Connect your AI

Cytokinetics CYTK Change in Deferred Revenue

Change in Deferred Revenue at other companies

VicorVICR

$0—

Broadridge Financial SolutionsBR

$27.9M+28.0%

Applied DigitalAPLD

-$396K+96.0%

Sanmina CorpSANM

-$19.22M-109%

Service Corporation InternationalSCI

$11.12M-30.7%

VicorVICR

-$104.25K-223%

Other financials

Income statement

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cytokinetics's change in deferred revenue?: Cytokinetics (CYTK) reported change in deferred revenue of $41K in Q1 2026.
What does change in deferred revenue mean?: The net change in cash received for work not yet completed.
How do you interpret change in deferred revenue?: An increase indicates strong future revenue visibility and upfront cash collection.
How does change in deferred revenue compare across companies?: Highly relevant for companies with long-term service contracts or milestone-based revenue.